Literature DB >> 22201710

Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides.

D Scott Wilbur1.   

Abstract

A review of chemical and radiochemical factors that must be considered when radiolabeling targeting agents with radionuclides is presented. The review discusses factors that are important in choice of radionuclide and choice of chelation or bonding reagents to use in the development of an α-emitting radiopharmaceutical. Chemical parameters, such as physical properties and pendant groups for radiolabeling, are reviewed. A major portion of the review outlines the development of chelates and labeling conditions for radiometals, and application of these reagents/conditions to radiometals. Acyclic and macrocyclic chelates containing amine and carboxylic acid coordination groups are highlighted, with examples of bifunctional chelates for biomolecule conjugation. Information is presented on over 60 radiometal-binding chelates. 211At radiolabeling is separated from that of radiometals, and the various reagents used for radiolabeling have been reviewed. Although not all 211At-labeling reagents are reviewed (due to another recent review), nearly 50 reagents studied in the development of pendant groups for labeling with 211At are described. The review also discusses how therapeutic doses of α-emitting radiopharmaceuticals can be affected by the radionuclide used and how radiation damage to the radiopharmaceutical can be minimized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22201710     DOI: 10.2174/1874471011104030214

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  13 in total

1.  Envisaging an alpha therapy programme in the atomic energy establishments: the priorities and the nuances.

Authors:  Sandip Basu; Sharmila Banerjee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-31       Impact factor: 9.236

2.  Enigmatic astatine.

Authors:  D Scott Wilbur
Journal:  Nat Chem       Date:  2013-03       Impact factor: 24.427

3.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

Review 4.  Molecular targeted α-particle therapy for oncologic applications.

Authors:  Thaddeus J Wadas; Darpan N Pandya; Kiran Kumar Solingapuram Sai; Akiva Mintz
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

5.  Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles.

Authors:  Oscar R Pozzi; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2016-12-10       Impact factor: 2.408

6.  Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.

Authors:  Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

Review 7.  Targeted alpha anticancer therapies: update and future prospects.

Authors:  Barry J Allen; Chen-Yu Huang; Raymond A Clarke
Journal:  Biologics       Date:  2014-11-10

8.  Synthesis and Characterization of the Actinium Aquo Ion.

Authors:  Maryline G Ferrier; Benjamin W Stein; Enrique R Batista; John M Berg; Eva R Birnbaum; Jonathan W Engle; Kevin D John; Stosh A Kozimor; Juan S Lezama Pacheco; Lindsay N Redman
Journal:  ACS Cent Sci       Date:  2017-02-01       Impact factor: 14.553

9.  Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Authors:  Darpan N Pandya; Roy Hantgan; Mikalai M Budzevich; Nancy D Kock; David L Morse; Izadora Batista; Akiva Mintz; King C Li; Thaddeus J Wadas
Journal:  Theranostics       Date:  2016-03-01       Impact factor: 11.556

10.  17AAG-induced internalisation of HER2-specific Affibody molecules.

Authors:  Lovisa Göstring; Sture Lindegren; Lars Gedda
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.